Wells Fargo & Company MN increased its stake in Applied Genetic Technologies Corporation (NASDAQ:AGTC) by 1.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,005 shares of the biotechnology company’s stock after buying an additional 200 shares during the period. Wells Fargo & Company MN owned approximately 0.11% of Applied Genetic Technologies Corporation worth $131,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of AGTC. CAPROCK Group Inc. raised its position in shares of Applied Genetic Technologies Corporation by 55.8% in the first quarter. CAPROCK Group Inc. now owns 17,215 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 6,165 shares during the last quarter. Tudor Investment Corp Et Al raised its position in shares of Applied Genetic Technologies Corporation by 20.6% in the fourth quarter. Tudor Investment Corp Et Al now owns 14,534 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 2,480 shares during the last quarter. Highbridge Capital Management LLC acquired a new position in shares of Applied Genetic Technologies Corporation during the fourth quarter valued at about $191,000. Teachers Advisors LLC raised its position in shares of Applied Genetic Technologies Corporation by 13.1% in the fourth quarter. Teachers Advisors LLC now owns 22,692 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 2,632 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Applied Genetic Technologies Corporation by 44.5% in the first quarter. Bank of Montreal Can now owns 56,732 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 17,481 shares during the last quarter. Institutional investors own 61.52% of the company’s stock.
Shares of Applied Genetic Technologies Corporation (NASDAQ AGTC) opened at 5.00 on Friday. The stock’s 50 day moving average is $5.04 and its 200-day moving average is $6.24. The stock has a market cap of $90.38 million, a P/E ratio of 11.93 and a beta of 1.68. Applied Genetic Technologies Corporation has a one year low of $4.50 and a one year high of $17.00.
Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by $0.04. The firm had revenue of $8.39 million during the quarter, compared to the consensus estimate of $10.39 million. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. The business’s revenue for the quarter was down 30.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 earnings per share. On average, equities analysts forecast that Applied Genetic Technologies Corporation will post $0.33 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Applied Genetic Technologies Corporation (NASDAQ:AGTC) Position Raised by Wells Fargo & Company MN” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/08/05/wells-fargo-company-mn-acquires-200-shares-of-applied-genetic-technologies-corporation-nasdaqagtc-updated.html.
Several brokerages recently issued reports on AGTC. Cantor Fitzgerald set a $15.00 price target on shares of Applied Genetic Technologies Corporation and gave the stock a “hold” rating in a research note on Wednesday, May 10th. Zacks Investment Research upgraded shares of Applied Genetic Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Stifel Nicolaus reduced their price objective on shares of Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, May 11th. HC Wainwright set a $16.00 price objective on shares of Applied Genetic Technologies Corporation and gave the company a “buy” rating in a research note on Saturday, June 10th. Finally, ValuEngine lowered shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $13.81.
Applied Genetic Technologies Corporation Company Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
